Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line R-FCM followed by rituximab maintenance in untreated chronic lymphocytic leukemia
2005-001569-33Phase 2Active
- Sponsor
- Hospital Clínic de Barcelona
- Start
- Sep 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, fludarabine, cyclophosphamide and mitoxantrone in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Hospital Clínic de Barcelona. Primary endpoints: Feasibility and toxicity of R-FCM plus rituximab maintenance and Response rate of R-FCM. Started Sep 2005; status: active.
02
Drugs
rituximabfludarabinecyclophosphamidemitoxantrone
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2005-001569-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001569-33.